Ellence (Epirubicin Vials) 200MG/100 ML

Ellence (epirubicin) is a chemotherapy medication used for cancer treatment. This 200MG/100 ML vial form is administered intravenously under medical supervision. Store between 2-8°C to maintain stability. Always follow healthcare provider instructions for safe use.

Strength

200MG/100 ML

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Pfizer

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ellence is used in chemotherapy regimens to treat various cancers, including breast cancer and certain types of leukemia. It belongs to the anthracycline class of drugs, which work by interfering with cancer cell growth. Patients often ask, 'what is epirubicin used for' in the context of cancer treatment protocols. It may be prescribed alongside other medications depending on individual treatment plans.

Side Effects

Ellence may cause temporary effects such as nausea, fatigue, or hair loss as the body responds to treatment. Some patients experience changes in urine color or skin sensitivity during therapy. These effects vary by individual and treatment duration. Healthcare providers monitor responses closely to manage any discomfort.

Precautions & Warnings

Store Ellence vials refrigerated between 2-8°C and protect from light. Avoid freezing to maintain potency. Handle with care to prevent accidental exposure; use gloves and dispose of properly. Patients should inform their healthcare team of any pre-existing conditions before starting treatment.

Avoid Interactions

Ellence may interact with other medications, including certain heart medications, blood thinners, or drugs that affect liver enzymes. Alcohol and herbal supplements should be discussed with a healthcare provider. Live vaccines are generally not recommended during chemotherapy. Always disclose all medications and supplements to your doctor.

Frequently Asked Questions

Epirubicin is primarily used in chemotherapy to treat certain cancers, including breast cancer and leukemia.

Ellence is given as an intravenous infusion by healthcare professionals in a clinical setting.

No, Ellence vials should be refrigerated between 2-8°C and protected from light.

Hair loss is a possible side effect during treatment with epirubicin.

Avoid alcohol, live vaccines, and unprotected sun exposure unless advised otherwise by your doctor.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.